Mr. Larry Latowsky reports
CANNTAB GRANTED 2ND PATENT FOR IMMEDIATE RELEASE CANNABIDIOL FORMULATION TABLETS
The Canadian Intellectual Property Office (CIPO) has allowed Canadian patent No. CA 3050150 to Canntab Therapeutics Ltd., related to its proprietary cannabidiol formulations with a priority date of Jan. 23, 2017. The term of the patent expires on Jan. 22, 2038.
Canntab's legal counsel on intellectual property, Gavin Bogle of Magyar, Bogle & O'Hara LLP, said: "The allowance of Canntab's patent by the Canadian Intellectual Property Office provides fundamental intellectual protection for Canntab's innovative tableting technology and validates the years of research and development the company has conducted. The company now has patent protection in Canada and the USA, providing an international scope to the company's expanding portfolio of issued patents."
Canntab believes its hard pill formulations are superior to all other medical cannabidiol (CBD) and tetrahydrocannabinol (THC) delivery systems since they are true pharmaceutical-grade delivery systems which provide for superior ingredient stability, enhanced bioavailability, and provide customizable and precise dosing, as opposed to the widely available gel caps and capsule products from other suppliers.
Larry Latowsky, chief executive officer of Canntab, said: "This is another major milestone that confirms our proprietary formulations are unique and differentiated from other product offerings in the global marketplace. Intellectual property is at the root of our value proposition and, having been granted our first Canadian patent and our second patent overall in less than five months, further confirms our leading position as the go-to company for precise dosage and pharmaceutical grade tablets for the medical market containing THC, CBD, or any combination of THC and CBD." Mr. Latowsky added, "We are particularly pleased with the opportunities that are being presented for us to provide solutions to the USA market with the anticipated regulatory changes contemplated by the Biden administration which we anticipate will allow us faster access to the largest medical cannabis market in the world."
To further advance its IP, Canntab intends to prove greater bioavailability through a blood level study at a third party clinical research organization (CRO). This study is currently in the planning phase and Canntab will provide further details on timing and results as soon as this information becomes available. Going forward, Canntab is able to provide extended-release formulations, whether the intended use is for medical, recreational or nutraceutical purposes, which will make it easier for doctors, patients and the average consumer to make Canntab products their preferred cannabinoid delivery option.
Canntab has filed more than a dozen patent applications in the United States and Canada for which two have now been granted or allowed. Canntab has developed both patented and patent pending technologies to deliver standardized medical cannabis extract from selective strains in a variety of extended-release/sustained-release pharmaceutical-grade delivery systems.
On Sept. 21, 2020, Canntab had announced that, pursuant to a filing made in March, 2017, the United States Patent and Trademark Office (USPTO) had issued U.S. patent No. 10,772,837 to Canntab, titled "Modified Release Multi-Layer Tablet Cannabinoid Formulations." The term of the patent expires on March 15, 2038. The patent granted was for Canntab's bilayer or multilayer tablets consisting of both instant-release (IR) and extended-release (XR) formulations with THC, CBD, and a variety of terpenes and other cannabinoids found in full-spectrum cannabis and hemp oil resin.
About Canntab Therapeutics Ltd.
Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as cannabis 3.0 by the company, Canntab's proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical-grade solutions which incorporate all the features one would expect from any prescription or over-the-counter medication sold in pharmacies around the world. These will include the following formulations -- once a day and extended release, both providing an accurate dose and improved shelf stability.
Canntab holds a cannabis standard processing and sales for medical purposes licence, a cannabis research licence, and an industrial hemp licence from Health Canada.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.